The Middle East is experiencing a surge in biotechnology merger and acquisition deals, driven by accelerated efforts by Gulf governments to localize pharmaceutical manufacturing, expand health technology capabilities, and secure strategic capacities through long-term partnerships, according to a new study by Grand View Research. The study indicates that deal activity in the region has reached a turning point, with Gulf Cooperation Council countries focusing on technology transfer, developing manufacturing contracts, expanding production infrastructure, and securing primary sources for the healthcare supply chain. These trends align with the strategic objectives of the United Arab Emirates.
